[转移性结直肠癌不同化疗方案的成本效益分析]

[Cost-effectiveness analysis of different chemotherapeutical regimens in metastatic colorectal cancer].

作者信息

Liu Tian-Shu, Yu Yi-Yi, Chen Ying-Yao

机构信息

Department of Medical Oncology, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China.

出版信息

Zhonghua Wei Chang Wai Ke Za Zhi. 2008 Mar;11(2):120-3.

PMID:18344076

Abstract

OBJECTIVE

To compare FOLFOX6 and FOLFIRI regimen in the treatment of metastatic colorectal cancer with cost-effective analysis.

METHODS

Cost-effective analysis was conducted based on the efficacy results of V308 clinical trial of FOLFOX6 and FOLFIRI regimen and the medical system price in Zhongshan hospital.

RESULTS

The minimal cost analysis showed FOLFIRI followed by FOLFOX6 had the cost of RMB 206365.78 Yuan for each patient during the whole treatment period, and RMB 170468.89 Yuan for the FOLFOX6 followed by FOLFIRI regimen. Incremental analysis showed FOLFIRI followed by FOLFOX6 regimen could prolong one month of overall survival with additional cost of RMB 39885.44 Yuan in each patient while compared with the regimen of FOLFOX6 followed by FOLFIRI.

CONCLUSIONS

Both FOLFOX and FOLFIRI regimens are able to prolong the survival time of patients with metastatic colorectal cancer, but cost of such treatments are still quite expensive for Chinese patients. FOLFOX6 regimen suggests better cost-effectiveness than FOLFIRI.

摘要

目的

通过成本效益分析比较FOLFOX6和FOLFIRI方案治疗转移性结直肠癌的效果。

方法

基于FOLFOX6和FOLFIRI方案的V308临床试验疗效结果及中山医院医疗系统价格进行成本效益分析。

结果

最小成本分析显示，FOLFIRI序贯FOLFOX6方案在整个治疗期间每位患者的成本为206365.78元，FOLFOX6序贯FOLFIRI方案为170468.89元。增量分析显示，与FOLFOX6序贯FOLFIRI方案相比，FOLFIRI序贯FOLFOX6方案可使总生存期延长1个月，每位患者额外成本为39885.44元。